UTMD · Utah Medical Products Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UTMD
this stock
Utah Medical Products Inc
|
$221.94M | +24.6% | -5.8% | 21.3 | 5.2% |
|
ISRG
Intuitive Surgical Inc
|
$130.41B | -34.8% | +20.5% | 42.4 | 2.2% |
|
BDX
Becton Dickinson & Co
|
$48.44B | — | +8.2% | — | 3.9% |
|
MDLN
Medline Inc.
|
$42.77B | -22.5% | +11.5% | — | 3.0% |
|
ALC
Alcon Inc
|
$31.92B | -16.2% | +10.5% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UTMD | -1.4% | -3.3% | +7.9% | -2.0% | +24.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -0.3% | -1.6% | -10.0% | -1.6% | +12.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.